Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (EAP)

This treatment has been approved for sale to the public.

Sponsor:

Gilead Sciences

ClinicalTrials.gov Identifier:

NCT00989807

First Posted: October 6, 2009

Last Update Posted: December 13, 2012

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

Brief Summary

This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Detailed Description

Not Provided

Study Type

Expanded Access

Intervention

Drug: Aztreonam lysine

Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily

Publications *

Not Provided

Recruitment Information

Expanded Access Status

Approved for marketing

Contacts

Contact information is only displayed when the study is recruiting subjects